作者
Sunil Acharya,Rafet Başar,May Daher,Hind Rafei,Ping Li,Nadima Uprety,Emily L. Ensley,Mayra Shanley,Bijender Kumar,Pinaki P. Banerjee,Luciana Melo Garcia,Paul Lin,Vakul Mohanty,Kun Hee Kim,Xianli Jiang,Yuchen Pan,Ye Li,Bin Liu,Ana Karen Nunez Cortes,Chenyu Zhang,Mohsen Fathi,Ali Rezvan,Melisa J. Montalvo,L. Sophia,Francia Reyes-Silva,Rejeena Shrestha,Xingliang Guo,Kiran Kundu,Alexander Biederstädt,Luis Muniz-Feliciano,Gary Deyter,Mecit Kaplan,Xin R. Jiang,Enli Liu,Antrix Jain,Jason Roszik,Natalie W. Fowlkes,Luisa M. Solis Soto,Maria Gabriela Raso,Joseph D. Khoury,Pei Lin,Francisco Vega,Navin Varadarajan,Ken Chen,David Marín,Elizabeth J. Shpall,Katayoun Rezvani
摘要
Abstract Multiple factors in the design of a chimeric antigen receptor (CAR) influence CAR T-cell activity, with costimulatory signals being a key component. Yet, the impact of costimulatory domains on the downstream signaling and subsequent functionality of CAR-engineered natural killer (NK) cells remains largely unexplored. Here, we evaluated the impact of various costimulatory domains on CAR-NK cell activity, using a CD70-targeting CAR. We found that CD28, a costimulatory molecule not inherently present in mature NK cells, significantly enhanced the antitumor efficacy and long-term cytotoxicity of CAR-NK cells both in vitro and in multiple xenograft models of hematologic and solid tumors. Mechanistically, we showed that CD28 linked to CD3Z creates a platform that recruits critical kinases, such as LCK and ZAP70, initiating a signaling cascade that enhances CAR-NK cell function. Our study provides insights into how CD28 costimulation enhances CAR-NK cell function and supports its incorporation in NK-based CARs for cancer immunotherapy.